Zhejiang Garden Biopharmaceutical announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., recently received the "Pharmaceutical Registration Certificate" for "Alendronate Sodium Tablets" approved and issued by the National Medical Products Administration. This pharmaceutical is mainly used for the treatment of osteoporosis in postmenopausal women and male osteoporosis to increase bone mass. It is classified as a Category B variety in the "National Essential Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog." According to relevant regulations, this product is regarded as having passed the consistency evaluation of the quality and efficacy of generic drugs. The acquisition of the pharmaceutical registration certificate will further enrich the company's product line, promote the upgrade of product capabilities, and have a positive impact on the company's development.